CRA leverages cross-functional expertise to deliver best-in-class services to clients in the Life Sciences sector including strategic consulting, IP litigation, antitrust, and transfer pricing. Life sciences companies have high-stakes transfer pricing issues due to their high-value IP and the risks embedded within the value chain. CRA’s transfer pricing economists have assisted numerous pre-clinical biotech companies with their initial international expansion and IP planning; and commercial-phase companies design and document intercompany pricing policies relating to their physical goods supply chains. CRA experts have provided expert witness reports in GlaxoSmithKline vs. Commissioner and in state transfer pricing disputes.
Meet our team
![Gregory Bell | Expert Witness | Charles River Associates]()
Gregory K. BellGroup Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com![]()
Rebel CurdVice President, Practice Leader of Transfer Pricing
Oakland
+1-510-595-3098 rcurd@crai.com![]()
David Kemphe/him/his
Vice President, Transfer Pricing Leader for Canada
Toronto
+1-416-323-5563 dkemp@crai.com![]()
![]()
Engagements
- 01Transfer pricing planning for the impacts of COVID-19CRA was engaged by a global medical equipment company to analyze, help implement and defend the cross-border allocation of financial and tax impacts of the...View engagement
- 02Withholding tax analysis for IP transfersSeveral jurisdictions, including Germany and Colombia, have withholding tax requirements for transfers of IP registered in their countries, irrespective...View engagement
- 03Global transfer pricing advisoryCRA was engaged by a leading global medical device company to provide global transfer pricing advisory. CRA has been instrumental in all parts of its transfer...View engagement